Company Information

Location

Cleveland, Ohio, US

CEO

Baiju Shah

Website

www.biomotiv.com

Arix has a strategic agreement with BioMotiv, a research accelerator associated with The Harrington Project for Discovery and Development, a $300m initiative for advancing medicine based at university hospitals in Cleveland, USA. Arix finances opportunities, alongside and independently of BioMotiv, gaining privileged access to innovations from leading US research institutions and universities, including: Stanford, Columbia, Yale, Johns Hopkins and others. BioMotiv gives Arix first-look and first-option over a number of early-stage oncology opportunities. So far, Arix has invested in OptiKira, a company working on the unfolded protein response spun out of UCSF.

Our Partners

Learn more about our other partners.